VTX-801 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 171 | ウィルソン病 | 3 |
171. ウィルソン病
臨床試験数 : 79 / 薬物数 : 77 - (DrugBank : 17) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 30
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-000963-22-DE (EUCTR) | 18/10/2021 | 10/03/2021 | A clinical trial: treatment of adult Wilson's Disease patients with gene therapy | A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients with Wilson’s Disease - GATEWAY clinical trial | Wilson's Disease MedDRA version: 20.0;Level: LLT;Classification code 10047988;Term: Wilson's disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: N/A Product Code: VTX-801 INN or Proposed INN: NA Other descriptive name: Adeno-associated viral vector serotype 3B encoding shortened human ATP7B | Vivet Therapeutics SAS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 16 | Phase 1;Phase 2 | United States;Denmark;Germany;United Kingdom | ||
| 2 | NCT04537377 (ClinicalTrials.gov) | September 3, 2021 | 19/8/2020 | A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease | A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients With Wilson's Disease | Wilson's Disease | Genetic: VTX-801 | Vivet Therapeutics SAS | NULL | Recruiting | 18 Years | 65 Years | All | 16 | Phase 1/Phase 2 | United States;Denmark;Germany;United Kingdom |
| 3 | EUCTR2020-000963-22-DK (EUCTR) | 05/07/2021 | 07/05/2021 | A clinical trial: treatment of adult Wilson's Disease patients with gene therapy | A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in AdultPatients with Wilson's Disease - GATEWAY clinical trial | Wilson's Disease MedDRA version: 20.0;Level: LLT;Classification code 10047988;Term: Wilson's disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: N/A Product Code: VTX-801 INN or Proposed INN: N/A Other descriptive name: Adeno-associated viral vector serotype 3B encoding shortened human ATP7B | Vivet Therapeutics SAS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 16 | Phase 1;Phase 2 | United States;Denmark;Germany;United Kingdom |